- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones
Published on Feb. 1, 2026
Got story updates? Submit your updates here. ›
ProMIS Neurosciences Inc., a clinical-stage biotechnology company, has announced a private placement financing of up to $175 million. The financing is expected to extend the company's cash runway into 2028 and enable the completion of its Phase 1b Alzheimer's disease clinical study, as well as support the execution of other key clinical milestones. The company expects to report blinded top-line data from the study in mid-2026 and 12-month top-line data toward the end of 2026.
Why it matters
This financing will provide ProMIS Neurosciences with the necessary resources to advance its pipeline of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's, ALS, and Parkinson's. The successful completion of the Phase 1b study for Alzheimer's disease could be a significant milestone for the company and potentially lead to further development and commercialization of its lead candidate, PMN310.
The details
The private investment in public equity (PIPE) financing is being co-led by Janus Henderson and Ally Bridge Group, with participation from other new and existing investors. The financing includes the issuance of 6,815,296 common shares, common share warrants, and pre-funded warrants. The company expects the upfront gross proceeds to be approximately $75 million, with the potential for up to an additional $100 million if the warrants are fully exercised.
- The financing is expected to close on February 3, 2026, subject to customary closing conditions.
- Blinded 6-month top-line data from the Phase 1b Alzheimer's disease study is expected in mid-2026.
- 12-month top-line data from the Phase 1b Alzheimer's disease study is expected toward the end of 2026.
The players
ProMIS Neurosciences Inc.
A clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases.
Janus Henderson
A global asset management firm that is co-leading the PIPE financing.
Ally Bridge Group
A global healthcare-focused investment group that is co-leading the PIPE financing.
Neil Warma
The Chief Executive Officer of ProMIS Neurosciences.
Guggenheim Securities
The lead placement agent for the PIPE financing.
What they’re saying
“We are pleased to have the support of such a high-caliber group of sophisticated healthcare investors in this transformational financing.”
— Neil Warma, Chief Executive Officer of ProMIS
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This financing will provide ProMIS Neurosciences with the necessary resources to advance its pipeline of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, potentially leading to significant progress in the development of treatments for conditions like Alzheimer's, ALS, and Parkinson's.
